Comparative effectiveness of dapagliflozin vs DPP-4 inhibitors on a composite endpoint of HbA1c, body weight and blood pressure reduction in the real world.

Mario Luca MorieriAgostino ConsoliGiorgio SestiFrancesco PurrelloAngelo AvogaroGian Poalo Fadininull null

Published in: Diabetes/metabolism research and reviews (2020)

T2D patients initiating the SGLT2i dapagliflozin had a greater probability of attaining a composite endpoint of clinically relevant reductions in HbA1c, body weight and SBP, compared to similar patients initiating a DPP-4i in the same period and healthcare setting.

Keyphrases

body weight
end stage renal disease
healthcare
blood pressure
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
peritoneal dialysis
type diabetes
metabolic syndrome
skeletal muscle
weight loss
hypertensive patients
patient reported
glycemic control